FIELD: medicine.
SUBSTANCE: presented inventions refer to biomedicine and concern a peptide having an ability to bind COMM domain, using it for producing compositions. The characterised peptide consists of the amino acid sequence HARIKpTFRRIKWKYKGKFW, wherein N-terminal is protected by acetylation, whereas D-amino acids present in positions of prolin-6 and leucine-11.
EFFECT: presented group of inventions allows treating malignant tumours by increasing a nuclear localisation of COMMD1 protein, which is associated with a decrease or blocking of malignant tumour cell proliferation.
7 cl, 9 dwg, 2 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMBINATION FOR TREATMENT AND/OR CHEMOSENSITISATION OF TUMOURS RESISTANT TO ANTICANCER DRUGS | 2007 |
|
RU2396974C2 |
OLIGOPEPTIDE COMPOUNDS AND THEIR APPLICATIONS | 2009 |
|
RU2549675C2 |
CHIMERIC PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER | 2010 |
|
RU2435783C1 |
MUC-1 PROTEIN CYTOPLASMIC DOMAIN PEPTIDES AS CANCER INHIBITORS | 2009 |
|
RU2539832C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT GROWTH | 2012 |
|
RU2595400C2 |
PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND PREVENTION | 2012 |
|
RU2641260C2 |
PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | 2012 |
|
RU2611197C2 |
PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND PREVENTION | 2012 |
|
RU2624049C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT GROWTH | 2012 |
|
RU2610428C2 |
PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOURS | 2017 |
|
RU2746123C2 |
Authors
Dates
2016-03-20—Published
2011-05-31—Filed